/PRNewswire/ REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting, taking.
/PRNewswire/ Announced eye care collaboration with AbbVie to develop and commercialize RGX-314 AbbVie and REGENXBIO form a strategic partnership combining.
REGENXBIO Reports Second Quarter 2021 Financial Results and Operational Highlights prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
REGENXBIO Reports Second Quarter 2021 Financial Results and Operational Highlights prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
REGENXBIO Reports First Quarter 2021 Financial Results and Operational Highlights
News provided by
Share this article
ROCKVILLE, Md., May 5, 2021 /PRNewswire/
Enrollment ongoing in ATMOSPHERE™, the first of two planned pivotal trials for the subretinal delivery of RGX-314 for the treatment of wet AMD
Continued progress and expansion of Phase II AAVIATE
® trial of RGX-314 utilizing in-office suprachoroidal delivery for the treatment of wet AMD
Began dosing in Phase I/II trial of RGX-121, a one-time gene therapy for MPS II, in pediatric patients over 5 years old
Completed dosing in Cohort 1 of ongoing trial of RGX-111, a one-time gene therapy for MPS I